Your browser doesn't support javascript.
loading
Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy.
Sakamoto, Tetsunori; Ajiro, Masahiko; Watanabe, Akira; Matsushima, Shingo; Ueda, Keiji; Hagiwara, Masatoshi.
Afiliação
  • Sakamoto T; Department of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Building C, 3Rd Floor, Yoshida-Konoe Cho, Sakyo-Ku, Kyoto, 606-8501, Japan.
  • Ajiro M; Present address: Japanese Red Cross Otsu Hospital, Otsu, 520-8511, Japan.
  • Watanabe A; Department of Anatomy and Developmental Biology, Kyoto University Graduate School of Medicine, Building C, 3Rd Floor, Yoshida-Konoe Cho, Sakyo-Ku, Kyoto, 606-8501, Japan. ajiro.masahiko.6e@kyoto-u.ac.jp.
  • Matsushima S; Department of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan. ajiro.masahiko.6e@kyoto-u.ac.jp.
  • Ueda K; Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, 606-8397, Japan.
  • Hagiwara M; Department of Drug Discovery Medicine, Kyoto University Graduate School of Medicine, Kyoto, 606-8501, Japan.
BMC Cancer ; 23(1): 71, 2023 Jan 20.
Article em En | MEDLINE | ID: mdl-36670405
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma de Kaposi / Herpesvirus Humano 8 / Linfoma de Efusão Primária / Neoplasias Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma de Kaposi / Herpesvirus Humano 8 / Linfoma de Efusão Primária / Neoplasias Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article